AR064538A1 - THERAPEUTIC AGENT FOR MIOPATIA CONTAINING INTERLEUCINE ANTAGONIST -6 AS ACTIVE INGREDIENT - Google Patents

THERAPEUTIC AGENT FOR MIOPATIA CONTAINING INTERLEUCINE ANTAGONIST -6 AS ACTIVE INGREDIENT

Info

Publication number
AR064538A1
AR064538A1 ARP070105906A ARP070105906A AR064538A1 AR 064538 A1 AR064538 A1 AR 064538A1 AR P070105906 A ARP070105906 A AR P070105906A AR P070105906 A ARP070105906 A AR P070105906A AR 064538 A1 AR064538 A1 AR 064538A1
Authority
AR
Argentina
Prior art keywords
antagonist
active ingredient
therapeutic agent
miopatia
interleucine
Prior art date
Application number
ARP070105906A
Other languages
Spanish (es)
Original Assignee
Nat Univ Corp Tokyo Med & Dent
Chugai Pharmaceutical Co Ltd
Riken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39562504&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR064538(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nat Univ Corp Tokyo Med & Dent, Chugai Pharmaceutical Co Ltd, Riken filed Critical Nat Univ Corp Tokyo Med & Dent
Publication of AR064538A1 publication Critical patent/AR064538A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Agente terapéutico para la miopatía inflamatoria capaz de suprimir notablemente los síntomas de la miopatía inflamatoria, tales como la infiltracion anomala de células inflamatorias en fibras musculares, y sin las desventajas de los agentes existentes, tales como un debilitamiento general de la resistencia inmunitaria. En concreto la presente se refiere a agentes terapéuticos para la miopatía inflamatoria caracterizados porque tienen un antagonista de IL-6 como ingrediente activo. Para los agentes terapéuticos para la miopatía inflamatoria, un primer aspecto dentro del antagonista de IL-6 es el anticuerpo anti receptor de IL-6 y un segundo aspecto dentro del antagonista de IL-6 es un anticuerpo monoclonal y por tanto preferidos.Therapeutic agent for inflammatory myopathy capable of significantly suppressing the symptoms of inflammatory myopathy, such as the anomalous infiltration of inflammatory cells in muscle fibers, and without the disadvantages of existing agents, such as a general weakening of immune resistance. Specifically, this refers to therapeutic agents for inflammatory myopathy characterized in that they have an IL-6 antagonist as an active ingredient. For therapeutic agents for inflammatory myopathy, a first aspect within the IL-6 antagonist is the anti-IL-6 receptor antibody and a second aspect within the IL-6 antagonist is a monoclonal antibody and therefore preferred.

ARP070105906A 2006-12-27 2007-12-26 THERAPEUTIC AGENT FOR MIOPATIA CONTAINING INTERLEUCINE ANTAGONIST -6 AS ACTIVE INGREDIENT AR064538A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006351695A JP2010095445A (en) 2006-12-27 2006-12-27 Therapeutic agent for inflammatory myopathy containing il-6 antagonist as active ingredient

Publications (1)

Publication Number Publication Date
AR064538A1 true AR064538A1 (en) 2009-04-08

Family

ID=39562504

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105906A AR064538A1 (en) 2006-12-27 2007-12-26 THERAPEUTIC AGENT FOR MIOPATIA CONTAINING INTERLEUCINE ANTAGONIST -6 AS ACTIVE INGREDIENT

Country Status (5)

Country Link
JP (1) JP2010095445A (en)
AR (1) AR064538A1 (en)
CL (1) CL2007003817A1 (en)
PE (1) PE20081547A1 (en)
WO (1) WO2008078715A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69839992D1 (en) 1997-03-21 2008-10-23 Chugai Pharmaceutical Co Ltd Prophylactic or therapeutic agents for the treatment of multiple sclerosis, with antagonist anti-IL6 receptor antibodies as the active ingredient
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
EP3192528A1 (en) 2002-02-14 2017-07-19 Chugai Seiyaku Kabushiki Kaisha Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
US8398980B2 (en) 2004-03-24 2013-03-19 Chugai Seiyaku Kabushiki Kaisha Subtypes of humanized antibody against interleuken-6 receptor
PE20091174A1 (en) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd LIQUID FORMULATION WITH HIGH CONCENTRATION OF ANTIBODY CONTENT
AU2010311567B2 (en) 2009-10-26 2015-03-26 Chugai Seiyaku Kabushiki Kaisha Method for the production of a glycosylated immunoglobulin
RU2013126477A (en) 2010-11-08 2014-12-20 Дженентек, Инк. INTEGRATED SCAN ANTIBODIES AGAINST IL-6 RECEPTOR
MX363403B (en) 2013-07-04 2019-03-22 Hoffmann La Roche Interference-suppressed immunoassay to detect anti-drug antibodies in serum samples.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3630453B2 (en) * 1994-09-30 2005-03-16 中外製薬株式会社 A therapeutic agent for immature myeloma cells comprising an IL-6 receptor antibody as an active ingredient
DK0783893T3 (en) * 1994-10-07 2012-05-29 Chugai Pharmaceutical Co Ltd INHIBITION OF ANNORMAL GROWTH OF SYNOVIAL CELLS USING IL-6 ANTAGONIST AS ACTIVE INGREDIENT
DE69839992D1 (en) * 1997-03-21 2008-10-23 Chugai Pharmaceutical Co Ltd Prophylactic or therapeutic agents for the treatment of multiple sclerosis, with antagonist anti-IL6 receptor antibodies as the active ingredient
PL201461B1 (en) * 1998-03-17 2009-04-30 Chugai Pharmaceutical Co Ltd Preventives or remedies for inflammatory intestinal diseases containing as the active ingredient il-6 antagonists
ATE350060T1 (en) * 1998-08-24 2007-01-15 Chugai Pharmaceutical Co Ltd AGENTS FOR PREVENTING OR TREATING PANCREATITIS WHICH CONTAIN ANTI-IL-6 RECEPTOR ANTIBODIES AS THE ACTIVE COMPONENT
UA80091C2 (en) * 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
KR20100120246A (en) * 2001-11-14 2010-11-12 센토코 오르토 바이오테크 인코포레이티드 Anti-il-6 antibodies, compositions, methods and uses
AR048210A1 (en) * 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd A PREVENTIVE AGENT FOR VASCULITIS.

Also Published As

Publication number Publication date
CL2007003817A1 (en) 2008-06-27
PE20081547A1 (en) 2009-01-18
JP2010095445A (en) 2010-04-30
WO2008078715A1 (en) 2008-07-03

Similar Documents

Publication Publication Date Title
AR064538A1 (en) THERAPEUTIC AGENT FOR MIOPATIA CONTAINING INTERLEUCINE ANTAGONIST -6 AS ACTIVE INGREDIENT
NI201400842A (en) PARASITICIDED ORAL VETERINARY COMPOSITIONS INCLUDING ACTIVE AGENTS OF SYSTEMIC ACTION, METHODS AND USES OF THE SAME.
CL2017002527A1 (en) Use of formyl 2 peptide receptor agonists to treat inflammatory eye diseases. (divisional of application n ° 2485-2015).
CY1123365T1 (en) COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENORECTOR AGENT ACTIVITY
AR060487A1 (en) PHARMACEUTICAL COMPOSITIONS OF ANTI-BODY ANTAGONISTS ANTI-CD40
CL2017002686A1 (en) Methods to treat or prevent migraine headache
UY32819A (en) PHARMACEUTICAL COMPOSITIONS OF OPTALMIC USE OF ANTAGONISTS OF DP2 RECEIVER
MX2011012691A (en) Combination of a tnf-alpha antagonist and a vegf antagonist for use in the treatment or prevention of diseases of the eye.
EA201390977A1 (en) COMBINATION OF OPIOID RECEPTOR AGONIST AND OPIOID RECEPTOR ANTAGONIST FOR THE TREATMENT OF PARKINSON'S Disease
CR20130126A (en) ANTI-OX40 ANTIBODIES AND METHODS OF USE OF THE SAME
UA112434C2 (en) ANTIGENCY BINDING SPECIFICALLY Binds to ALL
EA201391662A1 (en) CONNECTIONS WITH THE ACTIVITY OF ANTAGONISTS OF MUSCARINE RECEPTORS AND AGONISTS OF THE ADRENERGIC RECEPTOR BETA2
EA201170473A1 (en) MORPHINAN COMPOUNDS
DOP2013000253A (en) FORMULATION FOR ANTIBODY ANTI-a4ß7
CL2013002053A1 (en) Heterocyclic derivative compounds, glucagon receptor antagonists; pharmaceutical composition that includes it and its use in the treatment of diabetes and metabolic diseases. pct
EA201100691A1 (en) ANTAGONISTS OF LYSOPHPATIDIC ACID RECEPTORS
AR064388A1 (en) ANTI-NOTCH3 ANTAGONIST ANTIBODIES AND ITS USE IN THE PREVENTION AND TREATMENT OF DISEASES RELATED TO THE NOTCH3 RECEIVER
CL2011003160A1 (en) Heterocyclic derived compounds, cb2 modulators; pharmaceutical composition comprising them; and use in the treatment of rheumatic, autoimmune, inflammatory diseases, pain, among others.
UY31622A1 (en) ANTHOGONISTS OF AMINOALQUILBIFENILO N, N-DISUBSTITUIDOS OF PROSTAGLANDINA D2 RECEPTORS
CL2009000873A1 (en) Compounds derived from cyclohepta [b] pyridine, antagonists of the cgrp receptor; pharmaceutical composition; and use for the treatment of migraine b.
UY31570A1 (en) DERIVATIVES OF OXADIAZOL AGONISTS OF THE S1P1 RECEIVER. PHARMACEUTICAL COMPOSITIONS THAT INCLUDE IT AND PREPARATION PROCEDURES OF THE SAME
BR112013005145A2 (en) anti-cxcl13 antibodies and methods for their use
PE20141149A1 (en) MONOCLONAL ANTIBODIES AGAINST THE TISSUE FACTOR PATH INHIBITOR (TFPI)
CO6761356A2 (en) Anti-reception antibodies to chimericin cc (ccr4) 4 and uses thereof
EA201170043A1 (en) COMBINATION OF PILOKARPIN AND METIMAZOLE FOR THE TREATMENT OF CHARCO-MARI-TUTE DISEASE AND RELATED DISORDERS

Legal Events

Date Code Title Description
FB Suspension of granting procedure